FDA Wants Suicide Warning Removed From Weight-Loss Drugs

The US Food and Drug Administration found no increased risk of suicidal behavior or ideation linked to popular weight-loss drugs, the regulator said in a letter Tuesday, and asked companies to remove warnings about the potential risk from the medicines’ labels.

The decision lifts a cloud over the drugs from Eli Lilly & Co. and Novo Nordisk A/S, which have seen surging demand. The FDA said drugmakers should cut language about the risks from the labels of Lilly’s Zepbound and Novo’s Wegovy and Saxenda. Versions of the drugs approved for diabetes don’t carry the warnings, the FDA said.